Is NCT07416188 recruiting in Bethesda, MD?

Yes, NCT07416188 is currently recruiting participants at its Bethesda, MD location. This recurrent glioblastoma clinical trial is actively enrolling qualified participants.

How do I join the recurrent glioblastoma clinical trial in Bethesda?

To join this clinical trial in Bethesda, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Bethesda clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Recurrent Glioblastoma Clinical Trial in Bethesda, MD

About This Recurrent Glioblastoma Study in Bethesda

Background: Glioblastoma is a common brain cancer in adults. Treatment includes surgery, radiation, and chemotherapy. But this cancer can return after treatment and is often fatal. Researchers want to know if a study drug (LMP744) can kill glioblastoma tumor cells. Objective: To test LMP744 in people with glioblastoma. Eligibility: People aged 18 years or older with glioblastoma that returned after treatment. Design: Participants will be screened. They will have a surgery to remove a small sample of tumor tissue (biopsy) from the brain. This will be done under protocol 03-N-0164. They will stay in the clinic for 1 night. They will also have imaging scans and tests of their heart function. Participants will have a central line installed: A flexible tube will be inserted into a vein in the chest. It will be attached to a port under the skin. This port will be used to draw blood and give medicines without having to insert new needles into a vein. LMP744 will be given through the central line for 5 days in a row. Participants will remain in the clinic for this time. Participants will then have a second surgery to remove as much of their tumor as possible. They will remain in the clinic until they recover from the surgery. Then they will recover at home after surgery. Participants will return to the clinic to receive the study drug for 5 days in a row through the central line, once a month for up to 12 months. Blood tests, heart function tests, and periodic imaging scans will be repeated during these visits. Participants will continue to have telehealth visits every 3 months after they stop taking the drug.

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)

Who Can Participate

Inclusion Criteria

Participant must meet all the following inclusion criteria to be deemed eligible for this study:

Participants \>= 18 years of age

Tissue-based diagnosis of recurrent glioblastoma, IDH-wildtype by a neuropathologist

Karnofsky Performance Status (KPS) \>60

Willing to use effective birth control method --The effects of LMP744 on developing human fetuses are unknown. Therefore, females of childbearing potential and their male partners must be willing to use an effective method of contraception during the clinical study (hormonal, barrier, surgical, or abstinence) before study enrollment and for 6 months after the last dose of the study drug. If the female becomes pregnant or suspects she is pregnant while participating in this study, she must inform her treating physician immediately.

Agreeable to undergo craniotomy for brain biopsy and/or resection --Initial diagnostic biopsy under 03-N-0164 to confirm recurrent disease and obtain pre-treatment tissue. Only participants who were not expected to able to achieve a gross total resection of tumor will be included in the study.

Willing and able to appoint a durable power of attorney

Able to provide informed consent or have a legally authorized representative (LAR) to provide consent, if incapacitated.

Exclusion Criteria

An individual who meets any of the following criteria will be excluded from participation in this study:

Pregnant and/or nursing females --As LMP744 is a novel agent with the potential for teratogenic or abortifacient effects, pregnant and/or nursing females will be excluded from receiving drug

Significant medical co-morbidities that would compromise the participant s ability to tolerate LMP744 and which cannot reasonably be controlled (per the investigator s judgment, such as poorly controlled chronic kidney disease and/or poorly controlled congestive heart failure)

Social situations that would limit compliance with study requirements, such as chronic homelessness

Prior chemotherapy or biologic therapy completed within 4 weeks (6 weeks for nitrosoureas and mitomycin C) or a duration of 5 half-lives (whichever is shorter)

Additional malignancy diagnosed or requiring active treatment within 1 year of screening

Unable to undergo an MRI scan of the brain

Active autoimmune disease that requires systemic treatment within 2 years of screening

Cardiac disease

\>=2 coronary revascularization procedures

Cardiac Troponin T or I \>= 2x the institutional upper limit of normal at screening

Ejection fraction \<45% on screening echocardiogram

Chronic hypokalemia (K\<2.5 mmol/L)

Human Immunodeficiency Virus (HIV)

Known history of HIV

Positive HIV 1/2 at screening.

Active Hepatitis B or Hepatitis C infection at screening

Active infection requiring systemic antibacterial, antiviral or antifungal therapy \<7 days prior to initiation of study drug

Recipient of autologous or allogeneic T cells

Solid organ or tissue transplant recipients

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Bethesda?

Yes, this clinical trial (NCT07416188) has an active research site in Bethesda, MD that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Recurrent Glioblastoma Treatment Options in Bethesda, MD

If you're searching for recurrent glioblastoma treatment options in Bethesda, MD, this clinical trial (NCT07416188) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Bethesda research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced recurrent glioblastoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all recurrent glioblastoma clinical trials near you to find additional studies recruiting in your area.

Recurrent Glioblastoma Clinical Trial in Bethesda, MD

Expert Care in Bethesda

IRB Approved

No-Cost Care

Apply for This Bethesda Location

Why Participate?

Simple Process